首页|依洛尤单抗联合阿托伐他汀钙治疗冠心病合并高血脂的效果及安全性

依洛尤单抗联合阿托伐他汀钙治疗冠心病合并高血脂的效果及安全性

扫码查看
目的 探讨依洛尤单抗联合阿托伐他汀钙治疗CHD合并高血脂的效果及安全性.方法 102例CHD合并高血脂患者随机分为对照组(阿托伐他汀钙)和观察组(依洛尤单抗+阿托伐他汀钙),比较两组的疗效和不良反应.结果 治疗后,观察组的TG、TC、LDL-C、ApoB水平均低于对照组,LDL-C达标率高于对照组(P<0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05).结论 依洛尤单抗联合阿托伐他汀钙治疗CHD合并高血脂可下调患者的血脂水平,安全性尚可.
Effect and Safety of Evolocumab Combined with Atorvastatin Calcium in the Treatment of Coronary Heart Disease Compli-cated with Hyperlipidemia
Objective To explore the effect and safety of evolocumab combined with atorvastatin calcium in the treatment of CHD complicated with hyperlipidemia.Methods 102 patients with CHD complicated with hyperlipidemia were randomly divided into the control group(atorvastatin calcium)and the observation group(evolocumab+atorvastatin calcium).The efficacy and adverse reactions were compared between the two groups.Results After treatment,the levels of TG,TC,LDL-C,and ApoB in the observation group were lower than those in the control group,and the LDL-C compliance rate was higher than that in the control group(P<0.05).No significant difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Evolocumab combined with atorvastatin calcium in the treatment of CHD complicated with hyperlipidemia can lower patients'blood lipid levels,and the safety is still acceptable.

EvolocumabAtorvastatin calciumCHDHyperlipidemia

王本军、王高彪、付中华、陈丰毅

展开 >

郑州市第七人民医院药学部,河南郑州 450016

河南省人民医院药学部,河南郑州 450003

郑州市第七人民医院心内科,河南郑州 450016

依洛尤单抗 阿托伐他汀钙 CHD 高血脂

2024

临床医学工程
国家医疗保健器具工程技术研究中心

临床医学工程

影响因子:0.193
ISSN:1674-4659
年,卷(期):2024.31(4)
  • 9